Dendritic Cell-Based Immunotherapy in Myeloid Leukaemia: Translating Fundamental Mechanisms into Clinical Applications

摘要: Immunotherapy for leukaemia patients, aiming at the generation of anti-leukaemic T cell responses, could provide a new therapeutic approach to eliminate minimal residual disease (MRD) cells in acute myeloid (AML). Leukaemic blasts harbour several ways escape immune system including deficient MHC class II expression, low levels co-stimulatory molecules and suppres-sive cytokines. Therapeutic vaccination with dendritic (DC) is now recognized as an important investigational therapy. Due their unique antigen presenting capacity, immunosuppressive features leukaemic can be circumvented. DC successfully cultured from 60–70% patients show functional potential vivo. Alternatively, monocyte derived obtained time complete remission loaded leukaemia-specific antigens used vaccine. Several sources leukaemia-associated different methods loading onto have been attempt optimize antitumour responses apoptotic cells, necrotic lysates tumour-associated pep-tides. Currently, AML-derived line MUTZ-3, immortalized equivalent CD34+ precursor under investigation purposes. For effective intrinsic tolerant state patient must overcome. Therefore, development efficient safe adjuvants specific im-munotherapeutic programs should encouraged.